Causaly
Unlock R&D productivity with the most complete AI platform for life sciences.
Unlock R&D productivity with the most complete AI platform for life sciences.
Causaly is a United Kingdom-based startup that aims to unlock R&D productivity in the life sciences industry through its comprehensive AI platform. Founded in 2018, the company's platform is designed to revolutionize how data is sourced, analyzed, and utilized in critical decision-making processes in drug discovery and development. With a focus on supporting a wide range of complex knowledge workflows, Causaly's AI platform accelerates the journey from bench research and laboratory insights to the launch of life-changing therapies. The company recently secured a $60.00M Series B investment on 13 July 2023 from prominent investors including Visionaries Club, Index Ventures, Marathon Venture Capital, Iconiq Growth, Pentech Ventures, Olivier Pomel, and Alex Gorsky. With its innovative approach and strong investor backing, Causaly is well-positioned to make significant strides in reshaping the life sciences industry through AI-driven solutions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $60.00M | 7 |
|
13 Jul 2023 |
| Venture Round | $10.00M | - | 24 Oct 2022 | |
| Series A | $17.00M | 3 |
|
17 May 2021 |
| Series A | $4.80M | 3 |
|
20 Nov 2019 |
| Seed Round | $1.20M | 5 |
|
26 Jul 2018 |
19 AI healthtechs to watch, according to VCs
We care about your data, and we'd love to use cookies make your experience better.
